Reducing ADT from 36 to 18 months Improves Quality of Life, Does Not Reduce Survival
A randomized Phase III Trial of outcomes for high-risk prostate cancer patients treated with radiotherapy and either 36 or 18 months of androgen deprivation therapy has found “no difference in survival between the two groups, with the 18-month group experiencing a better quality of life.”
Conducted in Québec, Canada, the clinical trial was led by Dr. Luis Souhami of McGill University Health Centre, Department of Radiation Oncology.
From October 2000 to January 2008, 630 patients with high-risk prostate cancer [HRPC] were randomized, 310 to pelvic and prostate radiotherapy [RT] combined with 36 months (long arm) and 320 to the same RT with 18 months (short arm) of ADT.
“In localized high-risk prostate cancer [HRPC],” Dr. Souhami and co-investigators report, “our results support that 36 months is not superior to 18 months of ADT. ADT combined with RT can potentially be reduced to 18 months in selected men without compromising survival or quality of life [QoL]. Thus, 18 months of ADT appears to represent a valid option in HRPC.”
Available online (free access) in the October 2018 issue of the journal European Urology, the full report includes a Table of quality of life results , charts comparing patient characteristics in the 2 arms of the study and graphs of Survival benefits and Quality of life results.
Abdenour Nabid, Nathalie Carrier, André-Guy Martin, Jean-Paul Bahary, Céline Lemaire, Sylvie Vass, Boris Bahoric, Robert Archambault, François Vincent, Redouane Bettahar, Marie Duclos, Marie-Pierre Garant, Luis Souhami.
Associate Editor: Matthew Cooperberg. Statistical Editor: Andrew Vickers
Posted by J. Strax, October 9 2018.